Elite in Hemorrhagic Proctocolitis

Flavio A. Caprioli

Milan, IT 
Elite in Hemorrhagic Proctocolitis
Milan, IT 
OverviewLocationsClinical Research

Overview

Flavio Caprioli practices in Milan, Italy. Mr. Caprioli is rated as an Elite expert by MediFind in the treatment of Hemorrhagic Proctocolitis. His top areas of expertise are Viral Gastroenteritis, Colitis, Ulcerative Colitis, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 169 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 50 articles and participated in 1 clinical trial in the study of Hemorrhagic Proctocolitis.

Gender
Male

Locations

Milan, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
View 2 Less Clinical Trials

168 Total Publications

Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey.
Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey.
Journal: European journal of gastroenterology & hepatology
Published: June 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Caprioli's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile